Atossa Therapeutics, Inc.

ATOSCIK 0001488039 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K filed Mar 25, 2026. Sentiment + YoY language diff vs prior year. Read sections →

Signal:Mild positive shiftFull-doc fallback

Full filing:tone -0.0177Δ+0.001286% similar+338/-288 ¶

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

Recent 8-K announcements

Per-item disclosure feed. Item 2.02 is the earnings release.

May 8, 2026no items parsed May 8, 2026no items parsed Apr 16, 2026no items parsed Mar 25, 2026no items parsed Feb 20, 2026no items parsed

YoY shift: Neutral

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K. This filing is 0.12pp more bullish than last year's.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Atossa Therapeutics, Inc.

Name	Roles	Filings
Quay Steven C	OfficerDirector	8
Finn Jonathan	Director	6
Remmel H. Lawrence	Director	6
Chen Shu-Chih	Director	5
Galli Stephen J	Director	5

Showing 1-5 of 11

Per pagePage 1 of 3Next

All filings

50 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Oct 21, 2025	Daniel Mark James Chief Financial Officer	Holdings only	-	-	-

Filed		Top transaction	Shares	Price	Value